+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses



Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses



Archives of Internal Medicine 164(1): 40-44



Background: In randomized trials of secondary prevention, pravastatin sodium and aspirin reduce risks of cardiovascular disease. Pravastatin has a predominantly delayed antiatherogenic effect, and aspirin has an immediate antiplatelet effect, raising the possibility of additive clinical benefits. Methods: In 5 randomized trials of secondary prevention with pravastatin (40 mg/d), comprising 73900 patient-years of observation, aspirin use was also prescribed in varying frequencies, and data were available on a large number of confounding variables. We tested whether pravastatin and aspirin have additive benefits in the 2 large trials (Long-term Intervention With Pravastatin in Ischaemic Disease trial and the Cholesterol and Recurrent Events trial) that were designed to test clinical benefits. We also performed meta-analyses of these 2 trials and 3 smaller angiographic trials that collected clinical end points. In all analyses, multivariate models were used to adjust for a large number of cardiovascular disease risk factors. Results: Individual trials and all meta-analyses demonstrated similar additive benefits of pravastatin and aspirin on cardiovascular disease. In meta-analysis, the relative risk reductions for fatal or nonfatal myocardial infarction were 31% for pravastatin plus aspirin vs aspirin alone and 26% for pravastatin plus aspirin vs pravastatin alone. For ischemic stroke, the corresponding relative risk reductions were 29% and 31%. For the composite end point of coronary heart disease death, nonfatal myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or ischemic stroke, the relative risk reductions were 24% and 13%. All relative risk reductions were statistically significant. Conclusion: More widespread and appropriate combined use of statins and aspirin in secondary prevention of cardiovascular disease will avoid large numbers of premature deaths.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011729958

Download citation: RISBibTeXText

PMID: 14718320

DOI: 10.1001/archinte.164.1.40


Related references

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses. Perspectives in Vascular Surgery and Endovascular Therapy 17(1): 65-1-67, 2005

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis. Cardiovascular Revascularization Medicine 10(3): 195-196, 2009

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Journal of the American College of Cardiology 41(6 Supplement A): 526A, March 19, 2003

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. American Heart Journal 162(1): 115-24.E2, 2011

Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of Internal Medicine 257(5): 399-414, 2005

Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. American Journal of Medicine 125(2): E13-E13, 2012

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301(18): 1909-1919, 2009

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials. Yearbook of Anesthesiology and Pain Management 2010: 9-11, 2010

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovascular Diabetology 16(1): 134-134, 2017

The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. Journal of the Neurological Sciences 332(1-2): 92-96, 2014

Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. Journal of Hypertension, 2018

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Archives of Internal Medicine 162(19): 2197-2202, 2002

Prevention of cardiovascular disease: risks and benefits of aspirin. Journal of General Internal Medicine 5(5 Suppl): S54-S57, 1990

Meta analyses of trials of aspirin in cardiovascular disease. Leaf, A And P C Weber (Ed ) Atherosclerosis Reviews, Vol 21 Prevention And Noninvasive Therapy Of Atherosclerosis; International Workshop, Key West, Florida, Usa, November 30-December 2, 1989 Xiii+206p Raven Press: New York, New York, Usa Illus 145-150, 1990

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. Journal of Thoracic and Cardiovascular Surgery 143(3): 665-675.E4, 2012